The use of human deoxyribonuclease (rhDNase) in the management of cystic fibrosis

BioDrugs

Volumn 19, Issue 3, 2005, Pages 135-144

  Suri, Ranjan ^a,b  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DEOXYRIBONUCLEASE I; DORNASE ALFA; PLACEBO; RECOMBINANT ENZYME; RECOMBINANT HUMAN DEOXYRIBONUCLEASE; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

AIRWAY; CLINICAL TRIAL; COST CONTROL; CYSTIC FIBROSIS; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEALTH CARE COST; HOARSENESS; HUMAN; INFLAMMATION; LONG TERM CARE; LUNG CLEARANCE; LUNG DISEASE; LUNG FUNCTION; PATIENT SELECTION; PHARYNGITIS; PHYSIOTHERAPY; PREDICTION; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; SPUTUM; TREATMENT OUTCOME; VISCOELASTICITY;

ADMINISTRATION, INHALATION; CLINICAL TRIALS; CYSTIC FIBROSIS; DEOXYRIBONUCLEASE I; DRUG ADMINISTRATION SCHEDULE; HUMANS; NEBULIZERS AND VAPORIZERS;

EID: 22244473009     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200519030-00001     Document Type: Review

References (79)

1. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245 (4922): 1066-73
2. Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989; 245 (4922): 1059-65
3. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989; 245 (4922): 1073-80
4. Bobadilla JL, Macek M, Fine JP, et al. Cystic fibrosis: a worldwide analysis of CFTR mutations. Correlation with incidence data and application to screening. Hum Mutat 2002; 19 (6): 575-606
5. FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr 1993; 122 (1): 1-9
6. Pilewski JM, Frizzell RA. Role of CFTR in airway disease. Physiol Rev 1999; 79 (1 Suppl.): S215-55
7. Eliezer N, Sade J, Silberberg A, et al. The role of mucus in transport by cilia. Am Rev Respir Dis 1970; 102 (1): 48-52
8. Widdicombe JH, Widdicombe JG. Regulation of human airway surface liquid. Respir Physiol 1995; 99 (1): 3-12
9. Basbaum CB, Jany B, Finkbeiner WE. The serous cell. Annu Rev Physiol 1990; 52: 97-113
10. Bjorkander J, Bake B, Oxelius VA, et al. Impaired lung function in patients with IgA deficiency and low levels of IgG2 or IgG3. N Engl J Med 1985; 313 (12): 720-4
11. Christensen TG, Blanchard GC, Nolley G, et al. Ultrastructural localization of endogenous peroxidase in the lower respiratory tract of the guinea pig. Cell Tissue Res 1981; 214 (2): 407-15
12. Ellison RT, Giehl TJ. Killing of gram-negative bacteria by lactoferrin and lysozyme. J Clin Invest 1991; 88 (4): 1080-91
13. Chernick WS, Barbero GJ. Composition of tracheobronchial secretions in cystic fibrosis of the pancreas and bronchiectasis. Pediatrics 1959; 24: 739-45
14. Vasconcellos CA, Allen PG, Wohl ME, et al. Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin. Science 1994; 263 (5149): 969-71
15. Matsui H, Grubb BR, Tarran R, et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998; 95 (7): 1005-15
16. Konstan MW, Berger M. Current understanding of the inflammatory process in cystic fibrosis: onset and etiology. Pediatr Pulmonol 1997; 24 (2): 137-42
17. Potter J, Matthews LW, Lemm J, et al. Composition of pulmonary secretions from patients with and without cystic fibrosis. Am J Dis Child 1960; 100: 493-5
18. Smith AL, Redding G, Doershuk C, et al. Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis. J Pediatr 1988; 112 (4): 547-54
19. Shak S, Capon DJ, Hellmiss R, et al. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci U S A 1990; 87 (23): 9188-92
20. Lethem MI, James SL, Marriott C. The role of mucous glycoproteins in the rheologic properties of cystic fibrosis sputum. Am Rev Respir Dis 1990; 142 (5): 1053-8
21. Weller PH, Bush E, Preece MA, et al. Short-term effects of chest physiotherapy on pulmonary function in children with cystic fibrosis. Respiration 1980; 40 (1): 53-6
22. Desmond KJ, Schwenk WF, Thomas E, et al. Immediate and long-term effects of chest physiotherapy in patients with cystic fibrosis. J Pediatr 1983; 103 (4): 538-42
23. Reisman JJ, Rivington-Law B, Corey M, et al. Role of conventional physiotherapy in cystic fibrosis. J Pediatr 1988; 113 (4): 632-6
24. Khan TZ, Wagener JS, Bost T, et al. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995; 151 (4): 1075-82
25. Armstrong DS, Grimwood K, Carzino R, et al. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ 1995; 310 (6994): 1571-2
26. Konstan MW, Hilliard KA, Norvell TM, et al. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 1994; 150 (2): 448-54
27. Williams MT. Chest physiotherapy and cystic fibrosis: why is the most effective form of treatment still unclear [abstract]? Chest 1994; 106 (6): 1872-82
28. Thomas J, Cook DJ, Brooks D. Chest physical therapy management of patients with cystic fibrosis: a meta-analysis. Am J Respir Crit Care Med 1995; 151 (3 Pt 1): 846-50
29. Prasad SA, Main E. Finding evidence to support airway clearance techniques in cystic fibrosis. Disabil Rehabil 1998; 20 (6-7): 235-46
30. McIlwaine MP, Davidson AG. Airway clearance techniques in the treatment of cystic fibrosis. Curr Opin Pulm Med 1996; 2 (6): 447-51
31. Armstrong JB, White JC. Liquefaction of viscous purulent exudates by deoxyribonuclease. Lancet 1950; II: 739-42
32. Spier R, Witebsky E, Paine JR. Aerosolized pancreatic dornase and antibiotics in pulmonary infections. JAMA 1961; 178: 110-8
33. Lieberman J. Dornase aerosol effect on sputum viscosity in cases of cystic fibrosis. JAMA 1968; 205 (5): 312-3
34. Raskin P. Bronchospasm after inhalation of pancreatic dornase. Am Rev Respir Dis 1968; 98 (4): 597-8
35. Aitken ML, Burke W, McDonald G, et al. Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis: a phase 1 study. JAMA 1992; 267 (14): 1947-51
36. Hubbard RC, McElvaney N, Birrer P, et al. A preliminary study of aerosolized recombinant human deoxyribonuclease I in the sputum of cystic fibrosis patients. N Engl J Med 1992; 326 (12): 812-5
37. Ranasinha C, Assoufi B, Shak S, et al. Efficacy and safety of short-term administration of aerosolised recombinant human DNase 1 in adults with stable stage cystic fibrosis. Lancet 1993; 342 (8865): 199-202
38. Ramsey BW, Astley SJ, Aitken ML, et al. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis 1993; 148 (1): 145-51
39. Fuchs H, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994; 331 (10): 637-42
40. Shah PL, Bush A, Canny GJ, et al. Recombinant human DNase 1 in cystic fibrosis patients with severe pulmonary disease: a short-term double-blind study followed by six months open-label treatment. Eur Respir J 1995; 8 (6): 954-8
41. McCoy K, Hamilton S, Johnson CAC. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Chest 1996; 110 (4): 889-95
42. Quan JM, Tiddens HA, Sy JP, et al. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001; 139 (6): 813-20
43. Geller D. Aerosolized dornase alfa in cystic fibrosis: is there a role in the management in patients with early obstructive lung disease? Pediatr Pulmonol 1997; 24: 155-8
44. Geller DE, Eigen H, Fiel SB, et al. Effect of smaller droplet size of dornase alfa on lung function in mild cystic fibrosis: Dornase Alfa Nebulizer Group. Pediatr Pulmonol 1998; 25 (2): 83-7
45. Hodson ME, McKenzie S, Harms HK, et al. Dornase alfa in the treatment of cystic fibrosis in Europe: a report from the Epidemiologic Registry of Cystic Fibrosis. Pediatr Pulmonol 2003; 36 (5): 427-32
46. 1 decline in children and adolescents with cystic fibrosis: effect of predicted equations [abstract]. Am J Respir Crit Care Med 1998; 157 Suppl.: A129
47. Ramsey BW, Dorkin HL. Consensus conference: practical applications of pulmozyme. Pediatr Pulmonol 1994; 17 (6): 404-8
48. Shah PL, Scott SF, Geddes DM, et al. Two years experience with recombinant human DNase I in the treatment of pulmonary disease in cystic fibrosis. Respir Med 1995; 89 (7): 499-502
49. Shah PL, Conway S, Scott SF, et al. A case-controlled study with dornase alfa to evaluate impact on disease progression over a 4-year period. Respiration 2001; 68 (2): 160-4
50. Davies J, Trindale MT, Wallis C, et al. Retrospective review of the effects of rhDNase in children with cystic fibrosis. Pediatr Pulmonol 1997; 23 (4): 243-8
51. Milla CE. Long-term effects of aerosolised rhDNase on pulmonary disease progression in patients with cystic fibrosis. Thorax 1998; 53 (12): 1014-7
52. Shah PL, Scott SF, Fuchs HJ, et al. Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I. Thorax 1995; 50 (4): 333-8
53. Zach MS. The role of recombinant human DNase in the treatment of patients with cystic fibrosis: many promises, many problems. Thorax 1996; 51 (7): 750-5
54. Kueppers F, Fiel SB. Proteolytic activity of purulent secretions in patients with CF and bronchitis is increased by DNase [abstract]. Am Rev Respir Dis 1992; 145 Suppl.: A563
55. Rochat T, Pastore FD, Schlegel-Haueter SE, et al. Aerosolized rhDNase in cystic fibrosis: effect on leucocyte proteases in sputum. Eur Respir J 1996; 9 (11): 2200-6
56. Shah PL, Scott SF, Knight RA, et al. The effects of recombinant human DNase on neutrophil elastase activity and interleukin-8 levels in the sputum of patients with cystic fibrosis. Eur Respir J 1996; 9 (3): 531-4
57. Suri R, Marshall LJ, Wallis C, et al. Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. Am J Respir Crit Care Med 2002; 166 (3): 352-5
58. Costello CM, O'Connor CM, Finlay GA, et al. Effect of nebulised recombinant DNase on neutrophil elastase load in cystic fibrosis. Thorax 1996; 51 (6): 619-23
59. Paul K, Rietschel E, Ballmann M, et al. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med 2004; 169 (6): 719-25
60. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary: no. 45. London: BMJ Books, 2003
61. Oster G, Huse DM, Lacey MJ, et al. Effects of recombinant human DNase therapy on healthcare use and costs in patients with cystic fibrosis. Ann Pharmacother 1995; 29 (5): 459-64
62. Menzin J, Oster G, Davies L, et al. A multinational economic evaluation of rhDNase in the treatment of cystic fibrosis. Int J Technol Assess Health Care 1996; 12 (1): 52-61
63. Ollendorf DA, McGarry LJ, Watrous ML, et al. Use of rhDNase therapy and costs of respiratory-related care in patients with cystic fibrosis. Ann Pharmacother 2000; 34: 304-8
64. Nasr SZ, Kuhns LR, Brown RW, et al. Use of computerized tomography and chest x-rays in evaluating efficacy of aerosolized recombinant human DNase in cystic fibrosis patients younger than age 5 years: a preliminary study. Pediatr Pulmonol 2001; 31 (5): 377-82
65. Wojnarowski C, Eichler J, Frischer T, et al. RhDNase therapy in patients with CF: is it possible to predict lung function improvement [abstract]? Pediatr Pulmonol 1995; Suppl. 12: 237
66. Bollert FGE, Paton JY, Marshall TG, et al. Recombinant DNase in cystic fibrosis: a protocol for targeted introduction through n-of-1 trials. Eur Respir J 1999; 13 (1): 107-13
67. Suri R, Metcalfe C, Lees B, et al. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet 2001; 358: 1316-21
68. Daviskas E, Anderson SD, Gonda I, et al. Inhalation of hypertonic saline aerosol enhances mucociliary clearance in asthmatic and healthy subjects. Eur Respir J 1996; 9 (4): 725-32
69. King M, Dasgupta B, Tomkiewicz RP, et al. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I. Am J Respir Crit Care Med 1997; 156 (1): 173-7
70. Boucher RC. Human airway ion transport: part two. Am J Respir Crit Care Med 1994; 150 (2): 581-93
71. Rubin BK, Ramirez O, Zayas G, et al. Respiratory mucus from asymptomatic smokers is better hydrated and more easily cleared by mucociliary action. Am Rev Respir Dis 1992; 145 (3): 545-7
72. Ziment I. Respiratory pharmacology and theraputics. Philadelphia (PA): WB Saunders, 1978
73. Robinson M, Regnis JA, Bailey DL, et al. Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. Am J Respir Crit Care Med 1996; 153 (5): 1503-9
74. Robinson M, Hemming AL, Regnis JA, et al. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax 1997; 52 (10): 900-3
75. Riedler J, Reade T, Dalton M, et al. Hypertonic saline challenge in an epidemiological survey of asthma in children. Am J Respir Crit Care Med 1994; 150 (6 Pt 1): 1632-9
76. Eng PA, Morton J, Douglass JA, et al. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatr Pulmonol 1996; 21 (2): 77-83
77. Ballmann M, von der Hardt H. Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. Pediatr Pulmonol 1998; Suppl. 17: 343
78. Suri R, Grieve R, Normand C, et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax 2002; 57 (10): 841-6
79. Jones AP, Wallis CE. Recombinant human deoxyribonuclease for cystic fibrosis. Cochrane Database Syst Rev 2003; (3): CD001127